Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
ESMO Open. 2022 Apr;7(2):100409. doi: 10.1016/j.esmoop.2022.100409. Epub 2022 Feb 26.
In the last years we have witnessed tremendous advancements in the treatment landscape of metastatic breast cancer (MBC), leading to a progressive prolongation of progression-free survival and, in some cases, also of overall survival. This led to a substantial increase of advanced disease treatability. In the present review we comprehensively and critically describe the most significant progresses in the therapeutic scenario of MBC according to BC subtype. In particular, we reviewed studies reporting practice-changing data in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive and triple-negative BC, with also a hint to BRCA-related tumors and the emerging HER2-low-positive category.
在过去的几年中，我们见证了转移性乳腺癌（MBC）治疗领域的巨大进展，导致无进展生存期的逐渐延长，在某些情况下，总生存期也得到了延长。这导致晚期疾病的可治疗性大大增加。在本综述中，我们根据乳腺癌亚型全面、批判性地描述了 MBC 治疗领域的最重要进展。特别是，我们回顾了报告改变激素受体阳性/人表皮生长因子受体 2（HER2）阴性、HER2 阳性和三阴性乳腺癌具有临床实践改变数据的研究，并且还提到了与 BRCA 相关的肿瘤和新兴的 HER2 低阳性类别。
